Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
regn · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Regeneron Pharmaceuticals, Inc. (REGN) measures how much investors pay for each dollar of the company's trailing earnings. REGN's current PE ratio of 14.33x is calculated by dividing its stock price of $610.98 by its TTM earnings per share of $42.53. −15.8% discount vs 5Y avg 17.0x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 14 fiscal years · Front-end computedMinQ1 · 25%21.5x
MedianQ3 · 75%133.7x
Max
At 14.33x, REGN's current P/E is lower than in 7% of its annual fiscal year readings over the past 14 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Regeneron Pharmaceuticals, Inc.You REGN | $62.9B | 14.33x | -70.4% | $42.53 |
 Alnylam Pharmaceuticals, Inc. ALNY | $39.1B | 166.04x | +242.6% | $2.39 |
 argenx SE ARGX | $54.6B | 39.90x | -17.7% | $21.08 |
 Cigna Corporation CI | $76.4B | 12.29x | -74.6% | $22.40 |
 Cencora, Inc. COR | $53.3B | 38.98x | -19.6% | $8.02 |
 Elevance Health Inc. ELV | $90.4B | 13.73x | -71.7% | $25.53 |
 Genmab A/S GMAB | $15.2B | 19.86x | -59.0% | $1.55 |
Industry Average 6 peers with valid PE | — | 48.47x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 17.92x | $43.07 | +2.9% | |
2024-12-31 FY2024 | 17.42x | $40.90 | -26.5% | |
2023-12-31 FY2023 | 23.70x | $37.05 | +33.1% | |
2022-12-31 FY2022 | 17.81x | $40.51 | +115.5% | |
2021-12-31 FY2021 | 8.27x | $76.40 | -44.1% | |
2020-12-31 FY2020 | 14.80x | $32.65 | -23.6% | |
2019-12-31 FY2019 | 19.38x | $19.38 | +10.5% | |
2018-12-31 FY2018 | 17.54x | $21.29 | -51.8% | |
2017-12-31 FY2017 | 36.36x | $10.34 | -23.7% | |
2016-12-31 FY2016 | 47.65x | $7.70 | -51.5% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Regeneron Pharmaceuticals, Inc. (REGN) measures how much investors pay for each dollar of the company's trailing earnings. REGN's current PE ratio of 14.33x is calculated by dividing its stock price of $610.98 by its TTM earnings per share of $42.53.
Frequently asked questions
REGN pe ratio · 6 questionsREGN's current PE ratio is 14.33x as of 2026-06-08, based on a stock price of $610.98 and TTM EPS of $42.53. Data sourced from Financial Modeling Prep via REGN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Regeneron Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08